Compare SYRE & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | MTRN |
|---|---|---|
| Founded | 2013 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2015 | 2000 |
| Metric | SYRE | MTRN |
|---|---|---|
| Price | $42.92 | $138.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $60.13 | ★ $69.75 |
| AVG Volume (30 Days) | ★ 659.5K | 219.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.42% |
| EPS Growth | N/A | ★ 1178.57 |
| EPS | N/A | ★ 3.58 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.31 |
| Revenue Next Year | N/A | $7.57 |
| P/E Ratio | ★ N/A | $36.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.91 | $69.10 |
| 52 Week High | $45.76 | $172.03 |
| Indicator | SYRE | MTRN |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 43.61 |
| Support Level | $15.01 | $112.74 |
| Resistance Level | $45.76 | $152.99 |
| Average True Range (ATR) | 2.15 | 6.75 |
| MACD | -0.19 | -1.82 |
| Stochastic Oscillator | 67.85 | 26.39 |
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.